Skip Navigation


JAC Advance Access originally published online on January 22, 2009
Journal of Antimicrobial Chemotherapy 2009 63(4):713-715; doi:10.1093/jac/dkp002
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
63/4/713    most recent
dkp002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Livermore, D. M.
Right arrow Articles by Woodford, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Livermore, D. M.
Right arrow Articles by Woodford, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci

David M. Livermore*, Shazad Mushtaq, Marina Warner and Neil Woodford

Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK

Received 13 November 2008; returned 24 November 2008; revised 29 December 2008; accepted 30 December 2008

* Corresponding author. Tel: +44-20-8327-7223; Fax: +44-20-8327-6264; E-mail: david.livermore{at}hpa.org.uk

Background: TR-700 is the active moiety of TR-701 (DA-7157), a new oral/intravenous oxazolidinone prodrug. We examined its activity against linezolid-susceptible and -resistant staphylococci and enterococci.

Methods: MICs were determined by the CLSI agar dilution method.

Results: MICs of TR-700 were tightly clustered around 0.5 mg/L for linezolid-susceptible staphylococci and enterococci compared with 2 mg/L for linezolid. MICs for 52 linezolid-resistant isolates were raised, but only exceeded 4 mg/L for two Enterococcus faecium isolates homozygous for the G2576T 23S rRNA mutation and for one with an unknown mechanism of linezolid resistance.

Conclusions: TR-700 is 4- to 16-fold more active than linezolid and overcame most linezolid resistance in vitro.

Keywords: G2576T , Gram-positive cocci , TR-701


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
S. Lemaire, F. Van Bambeke, P. C. Appelbaum, and P. M. Tulkens
Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines
J. Antimicrob. Chemother., November 1, 2009; 64(5): 1035 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Paul-Satyaseela, S. S. Solanki, D. Sathishkumar, T. Bharani, V. Magesh, and S. Rajagopal
In vitro antibacterial activities of a novel oxazolidinone, OCID0050
J. Antimicrob. Chemother., October 1, 2009; 64(4): 797 - 800.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.